Ixazomib

BNF:: Immune system & malignant disease
Status:: Red
Decision Date:: March 2018

Comments

RED:

NICE TA870 - Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (Decision date - March 2023)

NHS England drug. Available through CDF

Red Drug Classifications

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)